Benjamin Richard Wheeler, Chief Financial Officer of Myriad Genetics Inc, filed a Form 4 on November 9, 2026, disclosing the acquisition of a time-based stock option covering 121,379 shares of common stock granted on November 6, 2026.

Key Highlights

  • Reporting person: Benjamin Richard Wheeler, Chief Financial Officer of Myriad Genetics Inc (NASDAQ:MYGN)
  • Grant date: November 6, 2026, with the option covering 121,379 shares of common stock
  • Exercise price: $5.92 per share, described as equal to the closing price of the issuer's common stock on the grant date
  • Vesting schedule: The option vests and becomes exercisable in full on November 6, 2029, subject to continued service through that date
  • Expiration date: November 6, 2036
  • Grant characterization: Described in the filing as "a one-time non-qualified stock option granted as a retention award" under the issuer's 2026 Employee, Director and Consultant Equity Incentive Plan
  • Price of derivative security: $0

Wheeler's Retention Option Grant Details at Myriad Genetics

According to the filing, Myriad Genetics Inc granted its Chief Financial Officer, Benjamin Richard Wheeler, a time-based non-qualified stock option on November 6, 2026. The option covers 121,379 shares of the company's common stock and carries an exercise price of $5.92, which the filing states equals the closing price of the issuer's common stock on the grant date. The price of the derivative security at acquisition is reported as $0.

The filing describes the award as "a one-time non-qualified stock option granted as a retention award" under the issuer's 2026 Employee, Director and Consultant Equity Incentive Plan. Per the explanation of responses, the option "vests and becomes exercisable in full on November 6, 2029, subject to the Reporting Person's continued service through that date and the terms and conditions of the Plan and the applicable award agreement." The option expires on November 6, 2036. Following the transaction, Wheeler's directly held derivative securities beneficially owned total 121,379.

The Form 4 was filed on November 9, 2026, with the date of earliest transaction listed as November 6, 2026. The form was filed by one reporting person and was signed by Justin Hunter on behalf of Benjamin R. Wheeler.

What Was Disclosed

Myriad Genetics CFO Benjamin Richard Wheeler received a retention stock option for 121,379 shares at an exercise price of $5.92, granted November 6, 2026, vesting in full on November 6, 2029, and expiring November 6, 2036, under the company's 2026 equity incentive plan.